Advent Technologies (ADN) Q1 2025 earnings summary

Executive summary

• Revenue for Q1 2025 was $0.1M, down 95% year-over-year, with a net loss of $3.3M, a 65% improvement from Q1 2024 due to cost reductions and lower R&D and admin expenses.

• The company secured a €34.5M EU Innovation Fund grant for the RHyno Project and advanced collaborations with Airbus and the US Department of Defense.

• Advent faces significant liquidity challenges, with $0.3M in cash and a $29.1M working capital deficit as of March 31, 2025.

• A reverse stock split (1-for-30) was completed in May 2024 to regain Nasdaq compliance.

Financial highlights

• Revenue declined to $0.1M from $2.7M year-over-year, mainly due to timing of contract liabilities and deferred revenue.

• Gross loss was $0.2M, compared to a gross profit of $2.3M in Q1 2024.

• Net loss from continuing operations was $3.3M, improved from $9.4M in Q1 2024.

• Adjusted EBITDA for Q1 2025 was $(2.7)M, compared to $(3.7)M in Q1 2024.

• Cash flow from operations was $0.3M, a turnaround from $(2.6)M in Q1 2024.

Outlook and guidance

• Management warns of substantial doubt about the company's ability to continue as a going concern without immediate additional funding.

• Projected inflows from revenues and grants are insufficient to cover outflows; delays or shortfalls could trigger insolvency.

• The company plans to finance operations through equity or debt sales and cost reductions, but success is uncertain.